Pancreatic Cancer Research

Clinical trialPhase 2Recruiting

Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

An Open-label, Randomized, Multicenter, Phase II Tripegfilgrastim Trial to Reduce the Risk of Severe Neutropenia in Patients With Unresectable Pancreaticobiliary Cancers

NCT06135896↗ ClinicalTrials.gov, retrieved 4 November 2026

Outcome
Ongoing
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Start
16 January 2024
Expected end
30 June 2026
Enrollment
98 participants
Sites
1
Primary outcomes
Primary endpoint
Sponsor
Other gov
Results posted
No
Last update
18 June 2025

These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.

Ask this document

Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.

Try

Papers 13